Boston Scientific reports preliminary data in the PREVAIL clinical trial met two out of three co-primary endpoints. The data was supposed to be presented during the 2013 American College of...
March 13, 2013 — St. Jude Medical Inc. announced the first patient implant in a new pivotal trial evaluating the company’s Amplatzer cardiac plug (ACP) for the prevention of stroke.
St. Jude Medical Inc. announced European CE mark approval of its Amplatzer Amulet Left Atrial Appendage Occluder. The Amulet device is used to close the left atrial appendage (LAA) in patients...
July 6, 2012 — Boston Scientific Corp. has completed enrollment in the PREVAIL confirmatory study, designed to gain U.S. Food and Drug Administration (FDA) approval...
May 14, 2012 — Boston Scientific announced results from the ASA Plavix (ASAP) Study, which studied the Watchman Left Atrial Appendage (LAA) Closure device. The data showed a reduction in the risk...
January 25, 2012 — Terumo Cardiovascular Systems announced today that it has entered into an exclusive agreement with LAAx Inc. to distribute the TigerPaw System II, a left atrial appendage (LAA)...
November 18, 2011 – Boston Scientific’s Watchman left atrial appendage (LAA) closure device has been implanted in the first patients in Latin America. The device is designed for use in patients in...
August 25, 2011 – Transcatheter structural heart occluder maker Occlutech said this week it closed a 15 million Euro investment in the company to accelerate its device development and bring it to...
May 23, 2011 -- Boston Scientific Corporation announced results from a clinical study evaluating the use of its Watchman Left Atrial Appendage Closure Device in patients with atrial fibrillation who...
May 18, 2011 - Jasbir Sra, M.D., and Tanvir Bajwa, M.D., are the first in Wisconsin to implant a new device in a patient’s heart that may reduce strokes in individuals suffering from atrial...
March 4, 2011 - Occlutech GmbH received a favorable court ruling in Stockholm, Sweden in the ongoing patent litigation case with AGA Medical-St. Jude Medical.
Boston Scientific has completed its acquisition of Atritech. The completion of the transaction follows the signing of a definitive merger agreement announced on Jan. 19, 2011.
Continuing to build a portfolio of transcatheter structural heart technology, Boston Scientific today signed a definitive merger agreement to acquire Atritech Inc. Atritech developed the Watchman...
November 3, 2010 – The first patient has been enrolled into a study comparing a left atrial appendage (LAA) closure device to warfarin therapy in those with atrial fibrillation. The PREVAIL study...
The first-in-man use of the Coherex WaveCrest left atrial appendage (LAA) occluder system was successfully performed recently in New Zealand, launching the WAVECREST 1 trial to evaluate the device...
St. Jude Medical Inc. said it plans to acquire AGA Medical Holdings Inc. for about $1.3 billion. The purchase will expand St. Jude’s cardiac device offerings with a portfolio of transcatheter...
October 4, 2010 – Germany will reimburse patients who have a left atrial appendage closure procedure in 2011. The 2011 G-DRG (German Diagnosis Related Group) catalog, recently published on the...
June 17, 2010 – AGA Medical Holdings Inc. this week announced first patient enrollment in the feasibility phase of the prospective, multicenter, randomized Amplatzer Cardiac Plug clinical trial....
June 16, 2010 – A new surgical device for excluding the left atrial appendage has received clearance from the U.S. Food and Drug Administration (FDA). AtriCure Inc. announced this week that it...
March 25, 2010 – The FDA this week granted permission for a conditional investigational device exemption (IDE) to evaluate the safety and efficacy of a transcatheter plug to seal the left atrial...
August 24, 2009 – Physicians at The Mount Sinai Medical Center were the first in the country to perform a nonsurgical procedure using sutures to tie off a left atrial appendage (LAA), which is the...
May 11, 2009 - Medtronic Inc. today announced the successful implant of its Cardioblate Closure Left Atrial Appendage Occlusion Device by Patrick McCarthy, M.D., co-director of the Bluhm...
April 2, 2009 - A device implanted in the heart using minimally invasive techniques may replace the most widely prescribed drug for stroke prevention in patients with nonvalvular atrial...
March 6, 2009 - Atritech Inc. will release PROTECT AF trial results on WATCHMAN LAA closure technology comparing the device to the current standard of care, warfarin therapy, in patients with non...
August 18, 2008 - Atritech Inc. today said it filed its pre-market approval application (PMA) with the FDA for its WATCHMAN Left Atrial Appendage (LAA) Closure Technology, which contains the...
